


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1 – 7 have been previously cancelled.

DL

8. (Currently amended) A compound having the formula VI



(VI)

or a pharmaceutically acceptable salt thereof, wherein:

- (a) A_1 , A_2 , A_3 , and A_4 are carbon;
- (b) R_1 is hydrogen or alkyl;
- (c) R_2 is oxygen or sulfur;
- (d) R_3 is hydrogen;
- (e) R_4 , R_5 , R_6 , and R_7 are optionally present and are each independently selected from (i) the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, $S(O)R$, SO_2NRR' , SO_3R , SR , NO_2 , NRR' , OH , CN , $C(O)R$, $OC(O)R$, $NHC(O)R$, $(CH_2)_nCO_2R$, and $CONRR'$ or (ii) any two adjacent R_4 , R_5 , R_6 , and R_7 taken together form a fused ring with the aryl portion of the oxindole-based portion of the indolinone;
- (f) n is 0, 1, 2, or 3;
- (g) R is H, alkyl or aryl;
- (h) R' is H, alkyl or aryl; and

(i) A is a pyrrole ring, optionally substituted at one or more positions with alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_nCO₂R or CONRR'.

9. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a compound according to Claim 8.

D-2
cost

10. (Original) A method of treating diseases related to unregulated tyrosine kinase signal transduction, the method comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound according to Claim 8.

11. (Original) A method for regulating tyrosine kinase signal transduction comprising administering to a subject a therapeutically effective amount of a compound according to Claim 8.